Why Gland Pharma Share Price Is Rallying? Check 3 Key Reasons Behind the Surge

Gland Pharma is expanding its complex injectable and contract development and manufacturing organisation (CDMO) platform as global pharmaceutical companies seek specialised sterile manufacturing partners. The company reported a 23 per cent YoY increase in consolidated revenue from operations to Rs 1,833.6 crore for the second quarter of financial year 2026-27 (Q2 FY27), while profit after Tax (PAT) rose 58 per cent to Rs 290.8 crore.

Why Gland Pharma Share Price Has Rallied? Check 3 Key Reasons

1. Revenue was also 2 per cent higher QoQ, although profit moderated from Rs 317 crore in the preceding quarter. The PAT margin nevertheless expanded to 16 per cent from 12 per cent a year earlier, reflecting better operating leverage and product mix. Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 53 per cent YoY to Rs 480.4 crore, with the EBITDA margin rising by five percentage points to 26 per cent.
2. The CDMO business contributed 45 per cent of quarterly revenue and grew 31 per cent YoY to Rs 822.7 crore. However, CDMO revenue was down 8 per cent QoQ, partly offset by the Critical Injectables business, which rose 11 per cent sequentially and 18 per cent YoY to Rs 1,010.9 crore. The United States remained the principal growth market, with revenue increasing 42 per cent YoY to Rs 1,179.5 crore. Europe revenue grew 30 per cent YoY to Rs 371 crore. For the first half of FY27, consolidated revenue rose 21 per cent YoY to Rs 3,633.9 crore and PAT climbed 52 per cent to Rs 607.7 crore. The half-year EBITDA margin improved to 27 per cent from 23 per cent.
3. Gland launched four molecules in the US during the quarter and filed 11 abbreviated new drug applications (ANDAs), receiving 10 approvals. Its cumulative US portfolio now includes 399 ANDA filings, of which 350 have been approved. The company is also progressing technology transfers under a global pharmaceutical CDMO partnership and has added further dossiers to that arrangement. On the regulatory front, its VSEZ facility received zero observations in a US Food and Drug Administration audit, while the Dundigal facility received four procedural observations in an audit concluded in October 2026.

As of 10:12 am on November 9, 2026, Gland Pharma was trading at Rs 3,348.35. The stock was at its stated 52-week high and was up 5.65 per cent from the previous close. Over the past year, the shares have gained 65.29 per cent, compared with a 0.55 per cent decline in the BSE 500 over the same period. Institutional ownership has also increased, with foreign institutional holding rising by 1.62 percentage points and domestic institutional holding increasing by 2.77 percentage points.

What This Means for Investors

The quarter supports Gland Pharma's strategy of shifting towards complex injectables and CDMO engagements, where technical capability, regulatory compliance and manufacturing scale can support stronger margins. US revenue growth and higher Critical Injectables sales helped offset sequential softness in CDMO revenue. The expansion in EBITDA margin to 26 per cent indicates that higher utilisation, launches and operating efficiencies are translating into improved profitability. The growing ANDA portfolio and ready-to-use infusion-bag pipeline could add future product opportunities, while new CDMO technology transfers may deepen customer relationships.

The result is constructive for earnings visibility, but sequential performance shows that product mix and CDMO project timing can still influence quarterly profitability. The key execution test will be conversion of complex-product programmes, including co-development products expected to begin commercialisation from FY29. Regulatory execution also remains central for a sterile-injectables manufacturer. At 41.74 times trailing 12-month earnings and 21.72 times enterprise value to EBITDA, the valuation reflects expectations of sustained growth, margin discipline and successful CDMO scale-up.

Disclaimer: The article is for informational purposes only and not investment advice.